====== Brigatinib ======

[[Brigatinib]] (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor)

Brigatinib, a next-generation [[ALK inhibitor]], shows promising activity in [[Anaplastic lymphoma kinase non small cell lung cancer]] that have previously received [[crizotinib]] with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients
((Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new 
generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 
2018 Feb 16. doi: 10.2217/fon-2017-0545. [Epub ahead of print] PubMed PMID:
29451020.
)).